8-K/A: Shineco Inc. Completes Acquisition of FuWang (HK) International, Bolstering Life Science Portfolio

Shineco Inc. finalizes the acquisition of 75% equity interest in FuWang (HK) International, expanding its presence in the medical equipment and software sector.

Summary

• Shineco Inc., through its subsidiary Shineco Life Science Group Hong Kong Co., Limited, has completed the acquisition of 75% of the equity interests in FuWang (HK) International Company Limited.
• The acquisition closed on May 12, 2025, following a stock purchase agreement dated March 20, 2025.
• The consideration for the acquisition included a cash payment of RMB 63.89 million (approximately US$8.89 million), the issuance of 3,400,000 shares of Shineco's common stock, and the transfer of 71.42% of Shineco's equity interest in Dream Partner Limited to the seller.
• Audited financial statements of FuWang (HK) as of June 30, 2024 and 2023, and unaudited financial statements for the period ended December 31, 2024, are included as exhibits.
• Unaudited pro forma condensed combined financial information is provided to illustrate the estimated impact of the acquisition on Shineco's financial statements.

Sentiment

Score: 4

Explanation: The acquisition itself is a positive strategic move, but the significant pro forma losses and preliminary nature of the purchase price allocation temper the overall sentiment.

Positives

• The acquisition expands Shineco's business into medical software and equipment.
• The inclusion of FuWang (HK)'s financial statements provides transparency into the acquired company's performance.
• Pro forma financial information offers insights into the potential combined financial impact of the acquisition.

Negatives

• The pro forma combined statements of operations show significant net losses for both the six months ended December 31, 2024, and the year ended June 30, 2024.
• The purchase price allocation is preliminary and subject to change, which could materially impact the financial statements.
• The unaudited pro forma condensed combined financial statements do not reflect all reclassifications necessary to conform Fuwang's presentation to that of the Company's.

Risks

• The final purchase price allocation may differ materially from the preliminary estimates.
• The integration of FuWang (HK) may present unforeseen challenges.
• The pro forma financial information may not be indicative of future performance.
• The company is subject to a lawsuit against Yangzhou Huaxin Medical Technology Co., Ltd. for the repayment of the bank loan and related interests.

Future Outlook

The document provides pro forma financial information to illustrate the estimated impact of the acquisition, but does not offer specific forward-looking guidance.

Industry Context

This acquisition reflects a trend of companies expanding their portfolios through strategic mergers and acquisitions to gain access to new markets and technologies within the life science sector.

Comparison to Industry Standards

• Without specific details on FuWang (HK)'s market share, growth rate, and profitability metrics compared to its peers, it's challenging to benchmark this acquisition against industry standards.
• Comparable acquisitions in the medical equipment and software space often involve multiples of revenue or EBITDA, which are not explicitly provided in this document.
• Companies like Medtronic, Siemens Healthineers, and Stryker are key players in the medical device industry, and their acquisition strategies often involve acquiring companies with innovative technologies or strong market positions.
• Similarly, in the medical software sector, companies like Cerner, Epic Systems, and Allscripts acquire smaller firms to enhance their product offerings and expand their customer base.

Legal Proceedings

• Jiangsu Bank Co, Ltd. commenced a lawsuit against Yangzhou Huaxin Medical Technology Co., Ltd., a business partner of the Company, for the repayment of a bank loan and related interests, with the Company having a joint liability guaranty.

Related Party Transactions

• During the six months ended December 31, 2024 and 2023, the Group entered into the following significant related party transactions: Purchase of equipment 1,404, Purchase of materials 2,095, Loan from related party 14,767 and 35,618, Advances to related party 26,715.

Stakeholder Impact

• Shareholders will be impacted by the issuance of new shares as part of the acquisition consideration.
• Employees of both Shineco and FuWang (HK) may experience changes as a result of the integration.
• Customers of FuWang (HK) may benefit from Shineco's resources and expertise.
• Suppliers of FuWang (HK) may see changes in their relationships with the company.

Next Steps

• Finalize the purchase price allocation based on detailed valuation analysis.
• Integrate FuWang (HK)'s operations into Shineco's existing business.
• Monitor the performance of the combined entity and assess the impact of the acquisition on Shineco's financial results.

Key Dates

Keywords

acquisition, FuWang (HK) International, Shineco Inc., financial statements, pro forma, medical equipment, medical software, merger